Patient case: 70-year-old male with prostate cancer; genetic feature: PTEN

Clinical trial: Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Summary: The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity.
  A phase II study looks at how effective a medication is at treating a specific type of cancer and collects information on the side effects of the study treatment.
  RET, ROS1, or NTRK fusion or increased MET or AXL activity gene leads to lung cancer cell growth. Cabozantinib is an oral medicine that inhibits of RET, ROS1, NTRK, MET, and AXL. In addition, this drug interferes with other cell pathways that also cause cancer cells to grow, form new blood vessels, and spread to other organs of the body. The goal of using cabozantinib is to shrink the cancer and to prevent it from growing
  Cabozantinib has been studied and shown to cause cancer shrinkage in other cancers such as medullary thyroid cancer and prostate cancer. We thus have a good idea of what side-effects it causes and can anticipate them.


Eligibility: Inclusion Criteria:
  A subject must fully meet all of the following criteria to be eligible for the study:
  1. The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable.
  2. Documented presence:
  Group A: KIF5B/RET or related variant RET fusions.
  Group B: any of the following aberrations
  ii. NTRK fusion iii. MET overexpression, amplification, or mutation iv. AXL overexpression, amplification, or mutation
  Group C: ROS1 infustion
  3. The subject is ≥ 18 years old on the day of consent.
  4. The subject has a Karnofsky performance status of > 70%.
  5. The subject has organ and marrow function and laboratory values as follows:
  1. Absolute neutrophil count (ANC) ≥ 1500/mm3 without colony stimulating factor support
  2. Platelets ≥ 100,000/mm3 Hemoglobin ≥ 9 g/dL
  3. Bilirubin ≤ 1.5 × the upper limit of normal (ULN). For subjects with known Gilbert's . disease, bilirubin ≤ 3.0 mg/dL
  4. Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) ≥ 30 mL/min. For creatinine clearance estimation, the Cockcroft and Gault equation should be used:
  Male: CrCl (mL/min) = (140 - age) × wt (kg) / (serum creatinine × 72) Female:
  Multiply above result by 0.85
  5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
  ≤ 3.0 × ULN if no liver involvement, or ≤ 5 × ULN with liver involvement
  6. Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (113.2 mg/mmol) creatinine or 24-hr urine protein of < 1 g
  7. Serum phosphorus, magnesium, and potassium ≥ LLN after adequate supplementation if necessary
  8. The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document. Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control. Women of childbearing potential must have a negative pregnancy test at screening.
  9. Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal.
  10. Postmenopause is defined as amenorrhea ≥ 12 consecutive months. Note:
  women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason.
  Exclusion Criteria:
  1. Any type of systemic anticancer agent (including investigational) within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter. Subjects on LHRH or GnRH agonists may be maintained on these agents.
  2. Prior treatment with cabozantinib
  3. Radiation therapy for bone or brain metastasis within 2 weeks, any other external radiation therapy within 4 weeks of first dose of study drug. Systemic treatment with radionuclides within 4weeks. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
  4. The subject has not recovered to baseline or CTCAE ≤ Grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant AEs.
  5. Known uncontrolled symptomatic brain metastases or cranial epidural disease; subjects previously treated and on stable dose of corticosteroids and/or anticonvulsants for >10 days, or not requiring such medications, are eligible. Baseline brain scans are not required to confirm eligibility.
  Radiation therapy for bone or brain metastases within 2 weeks before first dose of study drug; or any other external radiation therapy or systemic treatment with radionuclides within 4 weeks before first dose of study drug. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible
  6. The subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or Factor Xa inhibitors, or antiplatelet agents (eg, clopidogrel). Low dose aspirin (≤ 100 mg/day), low-dose warfarin (≤ 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permitted.
  7. The subject has experienced any of the following within 3 months before the first dose of study treatment:
  -  clinically-significant hematemesis or gastrointestinal bleeding
  -  Clinically-significant hemoptysis of ≥ 0.5 teaspoon (2.5ml) of red blood c. any other signs indicative of pulmonary hemorrhage
  8. The subject has radiographic evidence of cavitating pulmonary lesion(s)
  9. The subject has tumor in contact with invading major blood vessels
  10. The subject has any evidence of an endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib.
  11. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
  -  Cardiovascular disorders including Congestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate) or Class IV (severe) at the time of screening
  -  Concurrent uncontrolled hypertension defined as sustained BP ≥ 150 mm Hg systolic, or ≥ 90 mm Hg diastolic despite optimal antihypertensive treatment (Note: If there is any BP measurement that is performed within the screening period that is < 150 mm Hg systolic and <90 mm Hg diastolic, then BP does not meet definition of sustained.)
  ---- Any congenital history of long QT syndrome.
  -  Any of the following within 6 months before the first dose of study treatment:
  -  unstable angina pectoris
  -  clinically-significant cardiac arrhythmias
  -  stroke (including TIA, or other ischemic event) myocardial infarction
  -  thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter (e.g. vena cava filter) are not eligible for this study)
  -  Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:
  -  Any of the following within 28 days before the first dose of study treatmentF
  -  intra-abdominal tumor/metastases invading GI mucosa (malignant abdominal ascites does not constitute mucosal invasion)
  -  active peptic ulcer disease,
  -  inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis
  -  malabsorption syndrome
  -  Any of the following within 6 months before the first dose of study treatment:
  -  history of abdominal fistula
  -  gastrointestinal perforation
  -  bowel obstruction or gastric outlet obstruction
  -  intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more that 6 months ago. GI surgery (particularly when associated with delayed or incomplete healing) within 28 days. Note: Complete healing following abdominal surgery must be confirmed prior to initiating treatment with cabozantinib even if surgery occurred more that 28 days ago.
  -  Other disorders associated with a high risk of fistula formation including PEG tube placement within 3 months before the first dose of study therapy or concurrent evidence of intraluminal tumor involving the trachea and esophagus.
  -  Other clinically significant disorders such as:
  -  active infection requiring systemic treatment within 28 days before the first dose of study treatment
  -  serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment
  -  history of organ transplant
  -  concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment
  -  Major surgery (eg, thoracotomy, removal or biopsy of brain metastasis) within 3 months before Week 1 Day 1. Complete wound healing from major surgery must have occurred 1 month before Week 1 Day 1 and from minor surgery (eg, simple excision, tooth extraction) at least 10 days before Week 1 Day 1. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.
  -  history of major surgery as follows:
  12. The subject is unable to swallow tablets
  13. The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms 14 days before Week 1 Day 1
  14. The subject is pregnant or breastfeeding.
  15. The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation.
  16. The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.
  17. Uncontrolled concurrent malignancy that would limit assessment of efficacy of cabozantinib.

Relevance to patient case: not relevant